Where Strategy and Ethics Converge: Pharmaceutical Industry Pricing Policy for Medicare Part D Beneficiaries

Author： Balotsky Edward  

Publisher： Springer Publishing Company

ISSN： 0167-4544

Source： Journal of Business Ethics, Vol.84, Iss.1, 2009-01, pp. : 75-88

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Extraordinary Pricing of Orphan Drugs: Is it a Socially Responsible Strategy for the U.S. Pharmaceutical Industry?

By Hemphill Thomas  

Journal of Business Ethics, Vol. 94, Iss. 2, 2010-06 ,pp. : 225-242

Springer Publishing Company

Access to resources Recommend Favorite

Pharmaceutical Pricing and Reimbursement and the Broader Pharmaceutical Policy Environment

By  

SourceOECD Industry, Services & Trade, Vol. 2008, Iss. 12, 2008-09 ,pp. : 112-169

OECD Publishing

Access to resources Recommend Favorite

R&D and marketing integration in NPD in the pharmaceutical industry

By Rafiq Mohammed   Saxon Tim  

European Journal of Innovation Management, Vol. 3, Iss. 4, 2000-04 ,pp. : 222-231

Emerald Group Publishing Ltd

Access to resources Recommend Favorite

Characteristics of R&D expenditures in Japan's pharmaceutical industry

By Nivoix Sophie   Nguyen Pascal  

Asia Pacific Business Review, Vol. 18, Iss. 2, 2012-04 ,pp. : 225-240

Routledge Ltd

Access to resources Recommend Favorite

The effect of Medicare Part D on prescription drug composition and demand

By ZimmerDavidDepartment of Economics   Western Kentucky University   Bowling Green   Kentucky   United States  

Journal of Economic Studies, Vol. 42, Iss. 2, 2015-05 ,pp. : 170-185

Emerald Group Publishing Ltd

Access to resources Recommend Favorite